Stocktoria
NEOGENOMICS INC NEO
NEOGENOMICS INC (NEO) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $727.3M at a -14.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.7 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.212 |
| Retained earnings / assets | -0.319 |
| EBIT / assets | -0.085 |
| Equity / liabilities | 1.599 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NEO | NEOGENOMICS INC | 5/9 | 1.46 | — | +10.1% |
| BNBX | BNB PLUS CORP. | 2/9 | — | — | — |
| AIDX | 20/20 Biolabs, Inc. | 4/9 | — | — | — |
| ULS | UL Solutions Inc. | 6/9 | 3.1 | 60.8 | +6.4% |
| GOOG | Alphabet Inc. | 5/9 | 6.79 | 31.1 | +15.1% |
| MSFT | MICROSOFT CORP | 6/9 | 4.49 | 20.7 | +17.8% |
| META | Meta Platforms, Inc. | 4/9 | 5.34 | 23.1 | +22.2% |
About NEOGENOMICS INC
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
FAQ
Is NEO financially healthy?
NEOGENOMICS INC's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does NEO pay a dividend?
No, NEOGENOMICS INC does not currently pay a dividend.
How profitable is NEO?
In FY2025, NEOGENOMICS INC had a net margin of -14.9% and a return on equity of -12.9%.
What is the analyst price target for NEO?
The average Wall-Street price target for NEOGENOMICS INC is $15.06, about 8.3% below the recent price, from 9 analysts (consensus: buy).
Is NEO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on NEOGENOMICS INC: a Piotroski F-score of 5/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.